<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE345nnn/GSE345409/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE345409</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>CD39-stratified CD8+ tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma profiled by bulk RNA sequencing after ex vivo anti-PD-1 and polydatin treatment</name><description>Tumor-infiltrating lymphocytes were recovered from six untreated head and neck squamous cell carcinoma surgical specimens and pooled. CD8+ TILs were sorted by flow cytometry into CD39-negative, CD39-medium and CD39-high populations and cultured for 72 h under four conditions: vehicle only, anti-PD-1 (nivolumab), polydatin (a G6PD inhibitor), and the combination of anti-PD-1 and polydatin. Bulk RNA sequencing of the twelve resulting libraries was used to determine how CD39 expression level stratifies the transcriptional response to combined checkpoint blockade and metabolic inhibition.</description><dates><publication>2026/09/21</publication></dates><accession>GSE345409</accession><cross_references><GSM>GSM10002838</GSM><GSM>GSM10002837</GSM><GSM>GSM10002836</GSM><GSM>GSM10002846</GSM><GSM>GSM10002835</GSM><GSM>GSM10002839</GSM><GSM>GSM10002841</GSM><GSM>GSM10002840</GSM><GSM>GSM10002845</GSM><GSM>GSM10002844</GSM><GSM>GSM10002843</GSM><GSM>GSM10002842</GSM><GPL>34281</GPL><GSE>345409</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>